
    
      Duration of each part of the study for one participant:

      Total study duration: Up to 57 days.

        -  Screening: up to 28 days.

        -  Up to 29 days of safety observation following the IV BIVV001 dose administration (this
           period includes PK sampling up to the first 10 days following administration).
    
  